ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
2014
680
LTM Revenue $40.8M
LTM EBITDA n/a
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ImmunityBio has a last 12-month revenue of $40.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, ImmunityBio achieved revenue of $14.7M and an EBITDA of -$264M.
ImmunityBio expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See ImmunityBio valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $0.6M | $14.7M | XXX | XXX | XXX |
Gross Profit | n/a | n/a | XXX | XXX | XXX |
Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
EBITDA | -$436M | -$264M | XXX | XXX | XXX |
EBITDA Margin | -70126% | -1793% | XXX | XXX | XXX |
Net Profit | -$417M | -$583M | XXX | XXX | XXX |
Net Margin | -66972% | -3955% | XXX | XXX | XXX |
Net Debt | $569M | $416M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ImmunityBio's stock price is $3.
ImmunityBio has current market cap of $2.6B, and EV of $2.9B.
See ImmunityBio trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$2.9B | $2.6B | XXX | XXX | XXX | XXX | $-0.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ImmunityBio has market cap of $2.6B and EV of $2.9B.
ImmunityBio's trades at 71.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate ImmunityBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ImmunityBio and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $2.9B | XXX | XXX | XXX |
EV/Revenue | 197.0x | XXX | XXX | XXX |
EV/EBITDA | -11.0x | XXX | XXX | XXX |
P/E | -6.2x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -7.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpImmunityBio's NTM/LTM revenue growth is 294%
ImmunityBio's revenue per employee for the last fiscal year averaged $22K, while opex per employee averaged $0.5M for the same period.
Over next 12 months, ImmunityBio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ImmunityBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ImmunityBio and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 2271% | XXX | XXX | XXX | XXX |
EBITDA Margin | -1793% | XXX | XXX | XXX | XXX |
EBITDA Growth | -39% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | -1499% | XXX | XXX | XXX | XXX |
Revenue per Employee | $22K | XXX | XXX | XXX | XXX |
Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 1290% | XXX | XXX | XXX | XXX |
Opex to Revenue | 2434% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ImmunityBio acquired XXX companies to date.
Last acquisition by ImmunityBio was XXXXXXXX, XXXXX XXXXX XXXXXX . ImmunityBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was ImmunityBio founded? | ImmunityBio was founded in 2014. |
Where is ImmunityBio headquartered? | ImmunityBio is headquartered in United States of America. |
How many employees does ImmunityBio have? | As of today, ImmunityBio has 680 employees. |
Who is the CEO of ImmunityBio? | ImmunityBio's CEO is Mr. Richard Adcock. |
Is ImmunityBio publicy listed? | Yes, ImmunityBio is a public company listed on NAS. |
What is the stock symbol of ImmunityBio? | ImmunityBio trades under IBRX ticker. |
When did ImmunityBio go public? | ImmunityBio went public in 2021. |
Who are competitors of ImmunityBio? | Similar companies to ImmunityBio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of ImmunityBio? | ImmunityBio's current market cap is $2.6B |
What is the current revenue of ImmunityBio? | ImmunityBio's last 12-month revenue is $40.8M. |
What is the current EV/Revenue multiple of ImmunityBio? | Current revenue multiple of ImmunityBio is 71.2x. |
What is the current revenue growth of ImmunityBio? | ImmunityBio revenue growth between 2023 and 2024 was 2271%. |
Is ImmunityBio profitable? | Yes, ImmunityBio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.